查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836791

非小細胞肺癌藥物市場（依治療類型、治療線、生物標記表達及銷售管道）——2025-2032 年全球預測

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line Of Therapy, Biomarker Expression, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年非小細胞肺癌藥物市場將成長至 332 億美元，複合年成長率為 7.99%。

主要市場統計數據
基準年2024年 179.4億美元
預計2025年 194億美元
預測年份：2032年 332億美元
複合年成長率（%） 7.99%

不斷發展的非小細胞肺癌治療前景：關注臨床重點、付款人轉變和轉化前景

非小細胞肺癌 (NSCLC) 仍然是癌症治療的核心挑戰，需要整合臨床創新、支付者協調和營運準備。過去十年的進展擴大了治療選擇，也使決策路徑更加複雜，迫使臨床醫生和醫療系統在療效、毒性和長期管理之間尋求平衡。本分析強調了治療科學與系統層面必要性的交匯，為領導者在當前環境下指明了方向。

引言部分透過核准近期的法規核准、生物標記主導範式的演變以及組合方案對實踐模式的影響，為本書奠定了基礎。引言還重點介紹了最有可能帶來回報的戰略關注領域，包括最佳化可操作生物標記的診斷工作流程、使處方策略與實際結果保持一致，以及投資於證據生成以支持基於價值的合約。透過闡明問題和優先事項，本書為讀者提供了後續深入章節的簡明藍圖。

重塑非小細胞肺癌治療和發展中的治療流程和相關人員獎勵的新治療和診斷創新

非小細胞肺癌的治療格局正因科學創新、監管格局的演變以及新的治療模式而改變。免疫腫瘤學的改進、標靶藥物的最佳化以及聯合用藥策略正在推動治療方法順序和關鍵臨床試驗設計的變革。同時，監管機構越來越重視生物標記定義的人群和核准後證據，這加速了分層發展，但也對診斷能力和真實世界數據基礎設施的需求日益增加。

同時，支付方動態和價值框架正在轉向基於結果的安排，這迫使製造商和醫療系統在研發早期整合衛生經濟學和結果研究。診斷技術的進步，包括次世代定序和液態切片的廣泛應用，使得患者選擇更加精準，但需要在實驗室網路和臨床醫生教育方面進行投資。這些因素的共同作用正在創造一個新的競爭前沿，臨床差異化、診斷能力和商業性敏捷性將決定企業的長期定位。

評估2025年美國對非小細胞肺癌藥物供應鏈、臨床試驗和病患所取得的關稅

2025年美國關稅的實施將進一步加劇非小細胞肺癌治療藥物的供應鏈、臨床試驗物流和下游准入的複雜性。關稅帶來的成本壓力將波及原料藥採購、成品進口和生產計劃，使製造商、經銷商和供應商容易受到採購延遲和利潤壓力的影響。這些營運影響將直接影響依賴穩定供應的臨床項目以及需要跨地區庫存同步的上市活動。

此外，關稅可能會改變伴隨診斷用品和實驗室耗材的經濟狀況，從而限制生物標記檢測的快速普及。臨床試驗贊助者可能面臨支持國際臨床實驗試驗地點和運輸臨床實驗產品的成本增加，迫使他們調整方案並制定緊急時應對計畫。健康系統和付款方可能會加強利用率控制，以應對採購成本的增加，從而更加重視強力的真實世界證據，以證明比較價值並維持患者可及性。最終效果將是重新強調供應鏈的韌性、多樣化的籌資策略以及積極主動的相關人員參與，以減輕可及性中斷的影響。

細分分析揭示了治療類型的區別、治療方案的考慮、生物標記定義的隊列以及為治療方法採用提供資訊的管道動態

詳細查看詳細情形可發現治療方法選擇和商業性途徑如何在多個方面出現分歧。根據治療類型，化療、免疫療法和標靶治療是核心類別，其中免疫療法進一步分為 CTLA-4 抑制劑、PD-1 抑制劑和 PD-L1 抑制劑。在 CTLA-4 抑制劑中，Ipilimumab等藥物體現了聯合策略中使用的較老類型藥物的作用機制，而 PD-1 抑制劑（如Nivolumab和Pembrolizumab）和 PD-L1 抑制劑（如Atezolizumab、 Avelumab和Durvalumab）則展示了查核點抑制劑類別中的廣度及其在當前抑制劑類別中的廣度。標靶治療涵蓋 ALK 抑制劑、BRAF 抑制劑、EGFR 抑制劑和 ROS1 抑制劑，其中 EGFR 類藥物本身經歷了第一代、第二代和第三代藥物的發展，每一代都反映了療效、抗藥性管理和耐受性的改進。

一線、二線和三線治療各自表現出獨特的臨床和商業性動態。根據生物標記狀態，第一線治療包括化療、聯合治療、免疫治療和標靶治療。第二線及以上治療同樣結合了化療、聯合治療、免疫治療和分子標靶治療，其決策在很大程度上受到既往治療史、不斷發展的抗藥性機制和患者的功能狀態的影響。生物標記表達進一步將患者細分為 ALK 重排、EGFR 突變、PD-L1 高表達和 KRAS 突變定義的群組，從而區分了標靶治療、查核點抑制劑或聯合治療的合格。分銷管道細分——醫院藥房、線上藥房和零售藥房——影響著患者的獲取、配藥物流和依從性支持計劃，特別是對於依賴門診分銷的門診病人標靶治療。這些細分維度結合在一起形成一個複雜的矩陣，其中臨床療效、診斷能力和管道執行決定了採用模式和治療順序。

各地區非小細胞肺癌治療的治療方法採用、監管差異和醫療保健能力進行比較

區域動態顯著影響非小細胞肺癌 (NSCLC) 藥物的採用、資金籌措和管理方式。在美洲，報銷途徑和大型綜合醫療系統使得新型藥物能夠快速引入，但付款方要求和州級處方流程的多樣性要求製造商制定多方面的可及性策略。該地區的研究基礎設施支持著強大的本地臨床試驗活動和生物標記主導治療方法的快速應用，但可負擔性的爭論仍在影響著政策討論和覆蓋決策。

歐洲、中東和非洲呈現多種管理體制和支付模式，國家衛生技術評估流程和集中核准交互作用，導致病患取得藥物的時間安排各有不同。已建立衛生技術評估 (HTA) 框架的國家要求儘早證明比較有效性，而該地區的新興市場則強調成本控制，可能優先考慮學名藥和低成本替代品。亞太地區各國的診斷可近性和報銷情況差異顯著，而一些擁有高產能的市場正快速普及。群體遺傳變異，例如某些國家特定作用機制突變的盛行率較高，會影響臨床試驗設計和標靶藥物的優先排序。在所有地區，本地產能、診斷網路和政策環境都會影響新治療模式轉化為常規實踐的速度。

領先的生物製藥和診斷公司的策略概況，重點關注非小細胞肺癌領域的管道差異化、合作模式和商業化方法

非小細胞肺癌 (NSCLC) 領域的企業策略取決於在產品線差異化、夥伴關係模式和商業執行之間取得平衡。領先的研發機構正在投資強大的轉化項目，將機制洞察與生物標記開發相結合，從而實現更有針對性的標記策略，並實現與競爭對手的差異化定位。生物製藥公司、診斷供應商和委外研發機構之間的策略聯盟，利用互補優勢，加速生物標記檢驗，並擴大臨床試驗入組。

商業性方法強調整合病人支持、診斷賦能和支付方證據產生。成功的公司將圍繞著以結果為導向的敘事，協調醫療事務、市場准入和商業團隊，從而與醫療系統和支付方產生共鳴。此外，那些在產品組合管理方面展現出敏捷性的公司，例如將資源導向高價值組合和創新機制，往往能夠保持產品上市勢頭，並抓住臨床相關的利基市場。透過觀察競爭對手的行為，領導者可以發現夥伴關係機會、許可路徑和鄰近療法，從而在降低開發風險的同時擴大目標患者群體。

可操作的建議，幫助行業領導者最佳化臨床策略，加速治療方法採用，並調整商業模式以改善護理

產業領導者應採取一系列切實可行的優先事項，將科學進步轉化為持續的臨床和商業性成果。實施針對 ALK、EGFR、PD-L1 和 KRAS 的穩健檢測途徑，將最大限度地選擇合適的患者並縮短治療時間。其次，證據生成必須超越隨機試驗，涵蓋真實世界有效性和衛生經濟學分析，以支持報銷討論和基於結果的合約。

第三，供應鏈多元化和緊急計畫對於緩解阻礙藥物取得的關稅相關風險和地緣政治風險至關重要。第四，領導者應設計強調病人引導和依從性支持的商業模式，尤其要關注在醫院、線上或零售藥局銷售的口服標靶藥物。最後，建立跨部門夥伴關係——包括製造商、診斷供應商、支付方和醫療保健系統之間的合作夥伴關係——可以加速組合方案的採用，並實現風險共擔，使獎勵與患者療效相一致。

採用嚴格的混合方法，說明資料來源、專家訪談以及用於得出臨床、監管和商業性結論的分析框架

本研究採用嚴格的混合方法，結合一手資料和二手資料，整合臨床、監管和商業洞察。一手資料包括對腫瘤科醫生、付款方和診斷領域領導者的深入專家訪談、對付款方提交資料的審查以及臨床指南分析。二手資料包括同行評審文獻、監管備案文件和公開的臨床試驗註冊庫，以支持機制和結果數據。

此分析框架整合了定性輸入的主題編碼，並與已發表的療效和安全性資料進行三角比較。診斷盛行率和生物標記分佈在群體遺傳學和檢測基礎設施的背景下進行解讀。商業性結論源自於報銷途徑分析和相關人員回饋，旨在得出實際意義。方法學保障措施包括交叉驗證、假設的透明記錄以及臨床和市場准入專家的迭代評審，以確保穩健性。

結論性綜合強調了非小細胞肺癌治療的策略性曲折點、合作的必要性以及改善療效的途徑

最終總結強調了臨床創新、診斷驗證和策略性商業性執行的整合對療效的影響。最重要的曲折點是及時的生物標記檢測、彈性供應網路以及將新機制與有意義的患者獲益聯繫起來的證據生成。合作開發包括與診斷合作夥伴的共同開發、與付款方就真實世界療效指標達成一致，以及簡化複雜方案啟動和監測的整合照護模式。

同時優先考慮這些核心要素的領導者將更有能力將治療潛力轉化為持續的患者獲益。本結論強調了跨職能投資、與報銷相關人員的早期溝通以及持續從真實世界臨床結果中學習以根據新數據調整策略的必要性。透過關注這些切實可行的途徑，組織可以支持廣泛且公平地獲取非小細胞肺癌治療的進展。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 針對非小細胞肺癌EGFR和MET抗藥性路徑的新興雙特異性抗體療法
  • 擴大採用循環腫瘤 DNA 檢測來早期發現和監測非小細胞肺癌 (NSCLC) 的治療
  • 人工智慧成像和診斷整合，為 NSCLC 提供個人化治療方案和結果
  • 開發一種新型 KRAS G12C 抑制劑，可有效治療先前難治性 NSCLC 亞型
  • 增加下一代 ALK 抑制劑的投資，以克服非小細胞肺癌患者的抗藥性突變
  • 擴大輔助免疫治療試驗，評估早期非小細胞肺癌 (NSCLC) 術後查核點抑制劑的療效
  • 組織獨立的 NTRK 融合治療方法的興起使得針對整個基因譜的 NSCLC標靶治療成為可能
  • 基於奈米顆粒的藥物傳輸系統的進展提高了肺腫瘤特異性並降低了毒性
  • PD-1/PD-L1聯合治療與化療在非小細胞肺癌（NSCLC）第一線治療的核准及市場滲透核准
  • 使用新輔助化療通訊協定來提高非小細胞肺癌（NSCLC）的病理反應率正在迅速增加

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章非小細胞肺癌藥物市場（依治療類型）

  • 化療
  • 免疫療法
    • CTLA-4抑制劑
      • Ipilimumab
    • PD-1抑制劑
      • Nivolumab
      • Pembrolizumab
    • PD-L1抑制劑
      • Atezolizumab
      • Avelumab
      • Durvalumab
  • 標靶治療
    • ALK抑制劑
    • BRAF抑制劑
    • EGFR抑制劑
      • 第一代
      • 第二代
      • 第三代
    • ROS1抑制劑

9. 非小細胞肺癌藥物市場治療線

  • 第一行
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療
  • 第二行
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療
  • 第三次及以後
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療

第 10 章非小細胞肺癌藥物市場（依生物標記表達）

  • ALK 重新配置
  • EGFR突變體
  • PD-L1高表達
  • KRAS突變體

第11章非小細胞肺癌藥物市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第12章非小細胞肺癌藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章非小細胞肺癌藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章非小細胞肺癌藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Amgen Inc.
    • AstraZeneca PLC
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: MRR-036C5CF3B524

The Non-small Cell Lung Cancer Therapeutics Market is projected to grow by USD 33.20 billion at a CAGR of 7.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 17.94 billion
Estimated Year [2025] USD 19.40 billion
Forecast Year [2032] USD 33.20 billion
CAGR (%) 7.99%

An orientation to the evolving non-small cell lung cancer therapeutic landscape highlighting clinical priorities, payer shifts, and translational prospects

Non-small cell lung cancer (NSCLC) remains a central challenge in oncology practice, requiring a synthesis of clinical innovation, payer alignment, and operational readiness. Advances over the past decade have expanded treatment options and complicated decision pathways, driving clinicians and health systems to balance efficacy, toxicity, and long-term management considerations. This analysis foregrounds the intersection of therapeutic science and system-level imperatives to equip leaders with a clear orientation to the current environment.

The introduction sets the stage by contextualizing recent regulatory approvals, evolving biomarker-driven paradigms, and the impact of combination regimens on practice patterns. It also signals where strategic attention will most likely yield returns: optimizing diagnostic workflows for actionable biomarkers, aligning formulary strategies with real-world outcomes, and investing in evidence generation to support value-based contracting. By framing problems and priorities upfront, the reader gains a concise roadmap for the deeper sections that follow.

Emerging therapeutic and diagnostic innovations reshaping treatment algorithms and stakeholder incentives across non-small cell lung cancer care and development

The NSCLC landscape is undergoing transformative shifts driven by scientific innovation, regulatory evolution, and emergent care delivery models. Immuno-oncology refinements, targeted agent optimization, and combination strategies are changing the calculus for sequencing therapies and for the design of pivotal clinical trials. Concurrently, regulatory bodies increasingly emphasize biomarker-defined populations and post-approval evidence, which accelerates stratified development but raises demands on diagnostic capacity and real-world data infrastructures.

In parallel, payer dynamics and value frameworks are shifting toward outcomes-based arrangements, compelling manufacturers and health systems to integrate health economics and outcomes research earlier in development. Advances in diagnostics, including broader adoption of next-generation sequencing and liquid biopsies, enable more precise patient selection but require investment in lab networks and clinician education. Together, these forces are creating new competitive frontiers where clinical differentiation, diagnostic enablement, and commercial agility determine long-term positioning.

Assessment of 2025 United States tariffs on supply chains, clinical trials, and patient access to non-small cell lung cancer therapies

The introduction of United States tariffs in 2025 has introduced additional complexity across supply chains, trial logistics, and downstream access for NSCLC therapies. Tariff-driven cost pressures ripple through active pharmaceutical ingredient sourcing, finished product imports, and manufacturing schedules, which can create procurement delays and margin sensitivities for manufacturers, distributors, and providers. These operational impacts have direct implications for clinical programs that depend on uninterrupted supply and for launch activities that require synchronized inventory across regions.

Moreover, tariffs can alter the economics of companion diagnostic supply and laboratory consumables, potentially constraining rapid adoption of biomarker testing. Trial sponsors may face increased costs for international site support or for shipping investigational products, prompting protocol adjustments and contingency planning. Health systems and payers responding to increased acquisition costs may tighten utilization controls, which raises the importance of robust real-world evidence to demonstrate comparative value and to preserve patient access. The net effect is a renewed emphasis on supply chain resilience, diversified sourcing strategies, and proactive stakeholder engagement to mitigate access interruptions.

Segmentation analysis revealing treatment type distinctions, therapy line considerations, biomarker-defined cohorts, and channel dynamics informing therapy adoption

A granular view of segmentation reveals how therapeutic choices and commercial pathways diverge across multiple axes. Based on treatment type, core categories include chemotherapy, immunotherapy, and targeted therapy, with immunotherapeutic modalities further delineated into CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors. Within CTLA-4 inhibitors, agents such as ipilimumab exemplify older-class mechanisms used in combination strategies, while PD-1 inhibitors like nivolumab and pembrolizumab, and PD-L1 inhibitors such as atezolizumab, avelumab, and durvalumab, demonstrate the breadth of the checkpoint inhibitor class and its central role in current regimens. Targeted therapy spans ALK inhibitors, BRAF inhibitors, EGFR inhibitors, and ROS1 inhibitors, and the EGFR class itself unfolds across first-, second-, and third-generation agents, each generation reflecting improvements in potency, resistance profile management, and tolerability.

When viewed through the line-of-therapy lens, first-line, second-line, and third-or-later settings each present unique clinical and commercial dynamics, with first-line options encompassing chemotherapy, combination therapy, immunotherapy, and targeted therapy based on biomarker status. Second-line and later lines similarly incorporate chemotherapy, combination regimens, immunotherapy, and targeted approaches, but decisions are heavily influenced by prior exposure, evolving resistance mechanisms, and patient functional status. Biomarker expression further segments patients into groups defined by ALK rearrangement, EGFR mutation, high PD-L1 expression, and KRAS mutation, driving differential eligibility for targeted agents, checkpoint inhibitors, or combinations. Distribution channel segmentation - hospital pharmacy, online pharmacy, and retail pharmacy - shapes patient access, dispensing logistics, and adherence support programs, especially for oral targeted therapies that rely on outpatient distribution. Together, these segmentation dimensions create a complex matrix in which clinical efficacy, diagnostic capacity, and channel execution determine adoption patterns and therapeutic sequencing.

Comparative regional insights into therapeutic adoption, regulatory variation, and healthcare capacity shaping non-small cell lung cancer care across regions

Regional dynamics substantially influence how NSCLC therapeutics are adopted, financed, and administered. In the Americas, reimbursement pathways and large integrated health systems can facilitate rapid adoption of novel agents, but heterogeneity in payer requirements and state-level formulary processes means manufacturers must deploy multifaceted access strategies. The region's research infrastructure supports robust local trial activity and accelerated uptake for biomarker-driven therapies, but affordability debates continue to shape policy discourse and coverage decisions.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and payer models where national health technology assessment processes and centralized approvals interact to create varied timelines for patient access. Countries with established HTA frameworks require early demonstration of comparative effectiveness, while emerging markets within the region emphasize cost containment and may prioritize generics or lower-cost alternatives. Asia-Pacific is characterized by rapid adoption in some high-capacity markets alongside significant variability in diagnostic availability and reimbursement across nations. Variations in population genetics, such as higher prevalence of certain actionable mutations in specific countries, influence clinical trial design and prioritization of targeted agents. Across all regions, local manufacturing capacity, diagnostic networks, and policy environments determine how swiftly new therapeutic paradigms translate into routine care.

Strategic profiles of leading biopharmaceutical and diagnostics companies highlighting pipeline differentiation, partnership models, and commercialization approaches in non-small cell lung cancer

Company strategies in NSCLC are defined by how organizations balance pipeline differentiation, partnership models, and commercial execution. Leading firms invest in robust translational programs to link mechanism-of-action insights with biomarker development, enabling more targeted label strategies and differentiated positioning against competing agents. Strategic collaborations among biopharma, diagnostics providers, and contract research organizations accelerate biomarker validation and expand trial enrollment by leveraging complementary capabilities.

Commercial approaches emphasize integrated patient support, diagnostics enablement, and payer evidence generation. Successful companies align medical affairs, market access, and commercial teams around outcome-based narratives that resonate with health systems and payers. Additionally, firms that demonstrate agility in portfolio management - reallocating resources toward high-value combinations or novel mechanisms - tend to preserve launch momentum and capture clinically relevant niches. Observing competitor behaviors, leaders can identify partnership opportunities, licensing paths, and therapeutic adjacencies that reduce development risk while expanding addressable patient populations.

Actionable recommendations to enable industry leaders optimize clinical strategies, accelerate therapeutic adoption, and align commercial models to improve care

Industry leaders should pursue a set of actionable priorities to convert scientific advances into durable clinical and commercial outcomes. First, integrating diagnostic capacity with therapeutic launches is essential; implementing robust testing pathways for ALK, EGFR, PD-L1, and KRAS will maximize appropriate patient selection and reduce time-to-treatment. Second, evidence generation must extend beyond randomized trials to include real-world effectiveness and health economic analyses that support reimbursement discussions and outcomes-based contracting.

Third, supply chain diversification and contingency planning are critical to mitigate tariff-related and geopolitical risks that can interrupt access. Fourth, leaders should design commercial models that emphasize patient navigation and adherence support, particularly for oral targeted agents distributed through hospital, online, or retail pharmacies. Finally, fostering cross-sector partnerships - between manufacturers, diagnostics providers, payers, and healthcare systems - will accelerate adoption of combination regimens and enable shared-risk arrangements that align incentives around patient outcomes.

Rigorous mixed-method approach describing data sources, expert interviews, and analytical frameworks that inform clinical, regulatory, and commercial conclusions

This research applies a rigorous mixed-method approach combining primary and secondary evidence to synthesize clinical, regulatory, and commercial insights. Primary research included in-depth expert interviews with oncologists, payers, and diagnostics leaders, alongside payer dossier reviews and clinical guideline analyses. Secondary research encompassed peer-reviewed literature, regulatory filings, and publicly available clinical trial registries to corroborate mechanistic and outcomes data.

Analytical frameworks integrated thematic coding of qualitative inputs with triangulation against published efficacy and safety data. Diagnostic prevalence and biomarker distributions were interpreted in the context of population genetics and testing infrastructure. For commercial conclusions, reimbursement pathway analysis and stakeholder feedback were synthesized to derive practical implications. Throughout, methodological safeguards included source cross-validation, transparently documented assumptions, and iterative review with clinical and market access experts to ensure robustness.

Concluding synthesis emphasizing strategic inflection points, collaborative imperatives, and pathways to improve outcomes in non-small cell lung cancer care

The concluding synthesis distills where clinical innovation, diagnostics enablement, and strategic commercial execution converge to influence outcomes. The most consequential inflection points involve timely biomarker testing, resilient supply networks, and evidence generation that links novel mechanisms to meaningful patient benefit. Collaborative imperatives span co-development with diagnostics partners, alignment with payers on real-world outcome metrics, and integrated care models that streamline initiation and monitoring of complex regimens.

Leaders who prioritize these axes concurrently will be better positioned to translate therapeutic potential into sustained patient benefit. The conclusion underscores the need for cross-functional investment, early engagement with reimbursement stakeholders, and continuous learning from real-world outcomes to adapt strategies as new data emerge. By focusing on these practical pathways, organizations can support broad, equitable access to advances in non-small cell lung cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of bispecific antibody therapies targeting EGFR and MET resistance pathways in NSCLC
  • 5.2. Growing adoption of circulating tumor DNA assays for early detection and treatment monitoring in NSCLC
  • 5.3. Integration of AI-driven imaging and diagnostics to personalize NSCLC treatment selection and outcomes
  • 5.4. Development of novel KRAS G12C inhibitors demonstrating efficacy in previously refractory NSCLC subtypes
  • 5.5. Increasing investment in next-generation ALK inhibitors to overcome resistance mutations in NSCLC patients
  • 5.6. Expansion of adjuvant immunotherapy trials assessing checkpoint inhibitors post-surgery in early-stage NSCLC
  • 5.7. Rise of tissue-agnostic therapies leveraging NTRK fusions for targeted NSCLC treatment across genetic profiles
  • 5.8. Advancements in nanoparticle-based drug delivery systems improving lung tumor specificity and reducing toxicity
  • 5.9. Approval and market uptake trends of PD-1/PD-L1 combination regimens with chemotherapy in first-line NSCLC
  • 5.10. Surge in use of neoadjuvant immunochemotherapy protocols to enhance pathologic response rates in NSCLC

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-small Cell Lung Cancer Therapeutics Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
    • 8.2.1. CTLA-4 Inhibitors
      • 8.2.1.1. Ipilimumab
    • 8.2.2. PD-1 Inhibitors
      • 8.2.2.1. Nivolumab
      • 8.2.2.2. Pembrolizumab
    • 8.2.3. PD-L1 Inhibitors
      • 8.2.3.1. Atezolizumab
      • 8.2.3.2. Avelumab
      • 8.2.3.3. Durvalumab
  • 8.3. Targeted Therapy
    • 8.3.1. ALK Inhibitors
    • 8.3.2. BRAF Inhibitors
    • 8.3.3. EGFR Inhibitors
      • 8.3.3.1. First Generation
      • 8.3.3.2. Second Generation
      • 8.3.3.3. Third Generation
    • 8.3.4. ROS1 Inhibitors

9. Non-small Cell Lung Cancer Therapeutics Market, by Line Of Therapy

  • 9.1. First Line
    • 9.1.1. Chemotherapy
    • 9.1.2. Combination Therapy
    • 9.1.3. Immunotherapy
    • 9.1.4. Targeted Therapy
  • 9.2. Second Line
    • 9.2.1. Chemotherapy
    • 9.2.2. Combination Therapy
    • 9.2.3. Immunotherapy
    • 9.2.4. Targeted Therapy
  • 9.3. Third Or Later
    • 9.3.1. Chemotherapy
    • 9.3.2. Combination Therapy
    • 9.3.3. Immunotherapy
    • 9.3.4. Targeted Therapy

10. Non-small Cell Lung Cancer Therapeutics Market, by Biomarker Expression

  • 10.1. ALK Rearrangement
  • 10.2. EGFR Mutant
  • 10.3. High PD-L1 Expression
  • 10.4. KRAS Mutant

11. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Non-small Cell Lung Cancer Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Non-small Cell Lung Cancer Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Non-small Cell Lung Cancer Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Amgen Inc.
    • 15.3.2. AstraZeneca PLC
    • 15.3.3. BeiGene, Ltd.
    • 15.3.4. Bristol-Myers Squibb Company
    • 15.3.5. F. Hoffmann-La Roche Ltd.
    • 15.3.6. Merck & Co., Inc.
    • 15.3.7. Novartis AG
    • 15.3.8. Pfizer Inc.
    • 15.3.9. Regeneron Pharmaceuticals, Inc.
    • 15.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NO